

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Recce Pharmaceuticals Ltd (Company)
<b>ABN</b>	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	James Graham
<b>Date of last notice</b>	16 May 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect interest
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Mr. James Graham is the trustee of the J Graham Family Trust and a beneficiary of the trust Buttonwood Nominees Pty Ltd held on behalf of Mr James Graham
<b>Date of change</b>	7 October 2025
<b>No. of securities held prior to change</b>	<b>Direct Interest</b> 1. 389,712 Class B Performance Shares 2. 2,250,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026 3. 3,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029  <b>Indirect Interest</b> Mr. James Graham <J Graham Family A/c> 4. 356,250 Class B Performance Shares  Buttonwood Nominees Pty Ltd 5. 6,801,076 fully paid ordinary shares
<b>Class</b>	Class B Performance Shares

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	Nil
<b>Number disposed</b>	745,962
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$7.46
<b>No. of securities held after change</b>	<b>Direct Interest</b> <ol style="list-style-type: none"> <li>2,250,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026</li> <li>3,000,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029</li> </ol> <b>Indirect Interest</b> Buttonwood Nominees Pty Ltd <ol style="list-style-type: none"> <li>6,801,076 fully paid ordinary shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of class b performance shares pursuant to a selective buy-back approved by ordinary shareholders and class b performance shareholders at the meetings held on 6 November 2024.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

Interest after change	N/A
-----------------------	-----

**Part 3 – <sup>+</sup>Closed period**

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Recce Pharmaceuticals Ltd (Company)
<b>ABN</b>	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ms Michele Keryn Dilizia
<b>Date of last notice</b>	16 May 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	7 October 2025
<b>No. of securities held prior to change</b>	2,724,937 fully paid ordinary shares  577,212 Class B Performance Shares  1,500,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026  1,600,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029
<b>Class</b>	Class B Performance Shares
<b>Number acquired</b>	Nil
<b>Number disposed</b>	577,212
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$5.77

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<p>2,724,937 fully paid ordinary shares</p> <p>1,500,000 unlisted options each exercisable at \$1.56, expiring 22 February 2026</p> <p>1,600,000 unlisted options each exercisable at \$0.80, expiring 14 November 2029</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Cancellation of class b performance shares pursuant to a selective buy-back approved by ordinary shareholders and class b performance shareholders at the meetings held on 6 November 2024.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
---	-----

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.